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Background: The Seville Quality of Life Questionnaire (CSCV) was designed to assess quality of life in patients with
schizophrenia taking into account those facets particularly important in this disorder. The study aimed at applying
the CSCV to a sample of Mexican patients with psychosis in an effort further substantiates the psychometric
properties of the CSCV.
Methods: This cross-sectional study included 61 patients (56 % female) with psychosis. Item-scale and item-factor
correlations were analyzed, as well as scale-factor correlations. Cronbach’s Alpha and principal component analysis
with varimax rotation were used to assess internal consistency and construct validity, respectively.
Results: Analyses of both, disfavorable and favorable dimensions, showed a stronger item-scale than item-factor
correlation, in most cases significant, though. Internal consistency was significant and adequate; higher for scales
than for factors. For the disfavorable and the favorable scales 11 and 2 factors were obtained, respectively;
explained variance was low.
Conclusions: In this sample of Mexican patients it was replicated that the CSCV is a valid and reliable instrument
to assess quality of life in people with psychosis; the use of scale scores is recommended.
Keywords: Seville quality of life questionnaire, Schizophrenia, Psychosis, Quality of life, Mexico
Background
Paradigms in the assessment of human health have
been changing for decades. Human health is currently
defined as a state of complete physical, mental and so-
cial well-being, rather than the mere absence of disease
or illness [1]. Assessment of a patient’s health is no lon-
ger based solely on a clinician’s report of the illness, but
now includes the patients’ appraisal of their condition
as a vital input [2]. An intrinsic element of this new
perspective of health is quality of life (QoL), defined as
the individuals’ perception of their positions in life in
the context of the culture and value systems in which
they live and in relation to their goals, expectations,
standards and concerns [3]. The concept of QoL is in-
creasingly acknowledged as an important health index
and has garnered greater attention in both clinical prac-
tice and research.
Growing interest in the study of QoL in the healthcare
community has been driven by recognition of health’s
subjective dimension, as well as the increasing preva-
lence of chronic illnesses that require long-term, and in
some cases permanent, treatment. Greater numbers of
patients now receive adequate treatment that allows
them to control their symptoms, and even survive ill-
nesses that were previously treated as terminal. However,
this has created the challenge of procuring patient QoL
in addition to curing or controlling their ailment [2].
Mental health care must also face this challenge.
Traditionally, symptom presence and severity, patient
functional status and the adverse effects of medication
have been the most widely used outcome metrics in
psychiatric care. All are usually reported by clinical staff
(psychiatrists, psychologists, nurses, social workers)
and/or relatives, supporting the prevailing perspective
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that self-reporting by psychiatric patients is unreliable
[4]. However, advances in both pharmacological and
psychotherapeutic treatments have significantly im-
proved patients’ observed clinical status, making them
more qualified as informants of the subjective experi-
ence of their disorders.
Conceptual and methodological debate is still active
in this area [5, 6], but there is growing interest in the
study of QoL in psychotic patients [7–12]. Most studies
report on use of generic QoL questionnaires that are
useful to a degree, but may not comprehensively reflect
the particular experience of schizophrenia when com-
paring diverse samples (i.e. from the general population
or patients with disorders other than psychosis). For
schizophrenic patients, QoL depends on myriad factors,
including cultural and economic circumstances, societal
homogeneity, traditional role of the family, social sup-
port, and availability of mental health services [12]. A
consistent and negative association has been identified
between psychopathology and QoL [7], yet there is no
reason to consider the presence of symptoms in psychi-
atric patients as defining their QoL status. The possible
side effects (e.g. lethargy, fatigue) of the antipsychotics
used to control positive psychotic symptoms also need
to be accounted for since they can negatively impact
QoL [13, 14].
In response to this situation, a group of experts in
Spain developed the Seville Quality of Life Question-
naire (Cuestionario Sevilla de Calidad de Vida - CSCV)
to explore crucial aspects of QoL in schizophrenic pa-
tients. Their initial item set consisted of 126 items, but
this was reduced to 59 in the final instrument following
factorial analyses. The CSCV includes a disfavorable
scale (CSCV-D) with 46 items, and a favorable scale
(CSCV-F) with 13 items [13–16]. Accurate psychomet-
ric properties have been reported for this instrument in
samples from Spain [15] and Chile [17]. It has been ap-
plied in samples from Spain [18–21], Chile [22–25],
Peru [26], and Mexico [27]. Although it is targeted at
patients with schizophrenia and related psychosis, it
has also been found useful for patients with cases of se-
vere drug addiction [26].
The present study’s aim was to apply the CSCV to a
sample of Mexican patients with psychosis in an effort
further substantiate the psychometric properties of the
CSCV. A reliable and valid instrument is vital to asses-
sing QoL in psychotic patients because it helps to gener-
ate dependable research data that can be used to design,
implement and evaluate new clinical intervention strat-
egies. Previous studies suggest the CSCV as an effective
diagnostic option, particularly, but not limitedly, for
Spanish-speaking countries such as Mexico, but its psy-
chometric properties need to be confirmed in target
populations before it is applied widely.
Methods
Design and participants
Partial data were used from a cross-sectional study on
the QoL of psychotic patients and their primary care-
givers. The study was done in 2009 at the Yucatan Psy-
chiatric Hospital (Hospital Psiquiátrico Yucatán) in
Merida, Mexico. This is the only public institution in
the city offering specialized psychiatric care. Following
Declaration of Helsinki norms [28], the study protocol
was approved by the Bioethics Committee of the host
hospital. Patient inclusion criteria were: 1) age at onset
16–45 years; 2) primary current DSM-IV-TR [29] diagno-
sis of schizophrenia or other schizophrenia spectrum
psychotic disorder; and 3) inhabitant of Merida. Exclusion
criteria were: 1) a DSM-IV-TR diagnosis of affective, or-
ganic, or toxic psychosis [29]; 2) evident intellectual
disorder; 3) inadequate contact information; and 4) se-
vere symptomatology impeding patient self-reporting.
A review of clinical files according to these criteria
produced 161 potential cases; of which 103 patients
could be contacted (55 had moved away or were not
home, 3 had died). Five of the remaining candidates
were excluded due to severe symptomatology. The final
sample included 61 participants (56 % female) who
signed an informed consent form including a statement
of no economic compensation. None of the participants
was hospitalized.
Sample characteristics
Mean age of patients was 35.9 years (SD = 10.0) when
interviewed, and 29.1 years (SD = 9.8) at psychosis onset.
No differences by sex were observed. Thirty-four (56 %)
participants had an education level of middle school or
lower (up to 9th grade), and the remaining 27 (44 %) had
a partial/complete high school or above education level.
The DSM-IV-TR diagnoses for participants were 41 pa-
tients with schizophrenia (14 paranoid, 2 disorganized,
and 25 residual); and 20 patients with other types of
schizophrenia-spectrum psychoses (8 schizoaffective, 7
delusional, 2 schizophreniform, 2 brief, and 1 unspeci-
fied). Mean illness course was 6.7 years (SD = 1.9, range
3.8–11.2).
Clinical status was measured using the PANSS (Posi-
tive and Negative Syndrome Scale) [30], with possible
scores ranging from 1 (absent) to 7 (extreme). Mean
scores in the sample were 1.44 (SD = .52) for positive
symptoms, 1.67 (SD = .75) for negative symptoms and
1.55 (SD = .42) for the general psychopathology dimen-
sion. Mean GAF (Global Assessment of Functioning)
[29] score for the sample was 75.3 (SD = 16.5). No differ-
ences by sex were identified for any of the PANSS or
GAF scores.
Overall mean score for the CSCV-D was 1.71 (SD = .60,
range 1.00–3.37), with mean scores for the corresponding
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nine factors falling within a range of 1.60 to 1.85. Overall
mean score for the CSCV-F was 3.05 (SD = .68, range
1.54–4.00), and mean scores for the corresponding three
factors ranged from 2.89 to 3.15. No significant differences
were identified by sex when comparing the overall CSCV-
D and CSCV-F scores, and neither were differences found
between any of their corresponding factors.
Instruments
The CSCV [14, 15] includes 59 Likert scale items, ran-
ging from 1 (totally disagree) to 5 (totally agree). The
first 46 items correspond to the CSCV-D scale and are
grouped into nine factors; they refer to unpleasant, nega-
tive or unsatisfactory aspects (e.g. “I’m bored all the
time”, “I’m afraid of myself”, “Everything overwhelms
me”). The last 13 items, grouped in three factors, corres-
pond to the CSCV-F scale, and reflect pleasant, positive
and satisfactory aspects (e.g. “I like myself”, “I feel com-
fortable with my thoughts”, “I am capable of organizing
my daily life”). The dimensions and their corresponding
factors are listed in Table 1. Mean scores can be ob-
tained for the 12 factors and the 2 subscales by aver-
aging their corresponding items. Scores of 1 on the
CSCV-D and 5 on the CSCV-F reflect a significantly
high quality of life, with eventual psychopathological
problems having no or only minimal impact. Conversely,
scores of 5 on the CSCV-D and 1 on the CSCV-F repre-
sent a patient who estimates his/her QoL as extremely
unfavorable or negative, and considers aspects prototyp-
ical of good QoL to be absent. A mean CSCV-D score
between 3 and 5 identifies patients whose QoL is nega-
tively affected, regardless of their CSCV-F score [13].
Statistical analyses
Using the SPSS v.20 statistical package, a series of
analyses were run: 1) sample size adequacy (Kaiser-
Meyer-Olkin [KMO] index) and data normal distribu-
tion (Kolmogorov-Smirnov test, skewness and kurtosis)
for each scale; 2) correlations between each item with its
corresponding mean factor score and mean scale score; 3)
internal consistency of each scale and factor with
Cronbach’s α, and with scale-factor correlations; and
4) construct validity, estimating the underlying factors
with an exploratory principal component analysis with
orthogonal varimax rotation, retaining factors agreeing
with Kaiser’s criterion (a.k.a. root latent criterion)
(eigenvalue > 1) and items with at least a 0.40 commu-
nality value.
Results
Sample size adequacy and normal distribution of data
Kaiser-Meyer-Olkin (KMO) values for sample adequacy
were 0.55 for CSCV-D and 0.85 for CSCV-F. KMO stat-
istic varies between 0 (indicating a disperse pattern of
correlations; hence, factor analysis would be inappropri-
ate) and 1 (indicating correlations have a rather com-
pressed pattern; thus, factor analysis should yield reliable
and definite factors). A minimum of 0.5 is recom-
mended; yet, the closer to 1 the more reliability can be
presumed. Mean CSCV-D (D (61) = 0.12, p ≤ .05) and
CSCV-F (D (61) = 0.18, p ≤ .001) scores were not normally
distributed; kurtosis levels for CSCV-D (z = 0.0331)
scores and CSCV-F (z = 0.8212) scores were not signifi-
cant. Skewness was significant for both scales (CSCV-D,
z = 2.91, p ≤ .01; CSCV-F, z = 2.28, p ≤ .05) since partici-
pants reported a largely favorable QoL (agreeing mostly
with CSCV-F statements and largely disagreeing with
CSCV-D statements). In response, four kinds of correl-
ational analyses were run with the Spearman non-
parametric test.
Item-factor and item-scale correlations
All item-factor correlations were significant (p < 0.001),
as were all item-scale correlations (p < 0.01). When using
corrected scores (i.e. item 1 is correlated with the total
score obtained with all of its corresponding items but
item 1, and so on) correlation values decreased slightly
but remained significant (p < 0.05), save for the correla-
tions between items 39, 24, 27 and their corresponding
factors (“oddness” and “restrained hostility”). Item-factor
correlation values ranged from 0.21 to 0.72, and mean
correlation by factor ranged from 0.25 to 0.60.
Item-scale correlation values ranged from 0.33 to 0.77
for CSCV-D and from 0.36 to 0.75 for CSCV-F. Mean
item-scale correlations ranged from 0.47 to 0.64 (cor-
rected, from 0.45 to 0.62) for CSCV-D factors and from
0.59 to 0.69 (corrected, from 0.50 to 0.62) for CSCV-F
factors. All these correlation values fall within the mod-
erate range (≥ 0.30 and < 0.70). Given that item-scale
correlation values were not extreme (rs ≤ 0.30 or rs ≤ 0.90)
and all were significant, all original items were included
for the subsequent analyses (see summary, Table 1).
Bartlett’s test results were significant (p ≤ 0.001) for
both scales and all twelve factors; therefore the items
were assumed to be related. In addition, R-matrix deter-
minant values for all factors and the CSCV-F scale
ranged from 0.002 to 0.758, thus rejecting multicolli-
nearity (< 0.00001). Given that the items were not exces-
sively related, the factor analysis was continued.
Internal consistency and factor-scale correlations
Alpha (α) values were above 0.80 in both the CSCV-D and
CSCV-F scales, suggesting good internal consistency. All
twelve factors had an α value above 0.50. CSCV-D α
values ranged from 0.576 (“restrained hostility”) to 0.885
(“loss of energy”); mean = 0.728. CSCV-F α values ranged
from 0.671 (“self-esteem”) to 0.802 (“vital satisfaction”);
mean = 0.742 (Table 2).
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Correlation between the CSCV-D and CSCV-F was
moderate (−0.57) but significant (p ≤ .001). Correlations
below 0.80 were observed between CSCV-D and three of
its factors: “restrained hostility” (0.69), “automatisms”
(0.68) and “oddness” (0.72). The remaining six factors
scored from 0.80 to 0.93. Correlations between CSCV-F
and its corresponding factors ranged from 0.86 to 0.93.
Table 1 Item-factor and item-scale Spearman correlations (item
included in total score/item excluded in total score)
Disfavorable Scale (CSCV-D)
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Table 1 Item-factor and item-scale Spearman correlations (item
included in total score/item excluded in total score) (Continued)
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With N = 61, if rs ≥ 0.247, p ≤ 0.05; if rs ≥ 0.311, p ≤ 0.01; if rs ≥ 0.398, p ≤ 0.001
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Correlations between the nine CSCV-D factors varied
from 0.43 to 0.81, and between the three CSCV-F factors
they ranged from 0.66 to 0.78. All correlations were sig-
nificant (p ≤ 0.001). A very few significant correlations
between a scale and factors of the opposite scale were
observed, although the significance level was quite low:
between CSCV-D and favorable factors, from −0.46 to–
0.56; between CSCV-F and disfavorable factors, from
−0.29 and −0.67; favorable and disfavorable factors, from
−0.15 and −0.66.
Factor analysis
After rotation, eleven factors met Kaiser’s criterion,
explaining 77.4 % of the CSCV-D variance; the first fac-
tor explained 9.76 % and the following explained 9.53 %.
For variance in the CSCV-F, two factors met the criter-
ion after rotation, explaining 55.1 % of variance; the first
factor explained 32.0 % and the next 23.1 %. Loading
patterns did not clearly replicate the original nine factors
of the CSCV-D or three factors of the CSCV-F (Table 3).
Discussion
Development of the CSCV was aimed at meeting the need
for a tool to assess subjective QoL from the perspective of
schizophrenic patients. The present study expands on previ-
ous studies of the CSCV’s psychometric properties and rep-
licates its adequacy in a sample of patients from Mexico.
Analysis of the CSCV-D and CSCV-F scales showed that
the items were more strongly correlated to their scale than
to their corresponding factors; however, in almost all cases
results were significant. Mean correlations by factor between
each scale (CSCV-D and CSCV-F) and its items showed a
similar pattern of moderate values.
Internal consistency was significant and satisfactory; it was
notably higher in scales than in factors. These results and
values are comparable to those previously reported for this
instrument with samples from Spain (CSCV-D, α= 0.94;
CSCV-F, α = 0.85) [15] and Chile (CSCV-D, α = 0.962;
CSCV-F, α= 0.897) [17]. The pattern of factor α values is
also comparable to a study done in Chile [17]: CSCV-D
from 0.350 (“restrained hostility”) to 0.830 (“loss of energy”),
mean = 0.648; CSCV-F from 0.697 (“harmony”) to 0.772
(“vital satisfaction”), mean = 0.732. Given the factor-scale
correlations, the disfavorable and favorable scales are clearly
differentiated.
Factor analysis results agree with the number of fac-
tors obtained in a sample from Chile [17] (CSCV-D: 11,
CSCV-F: 2), but differ from those reported in the ori-
ginal study [15] (CSCV-D: 9, CSCV-F: 3). Total ex-
plained variance was low (CSCV-D: 77.40 %; CSCV-F:
55.14 %), but higher than reported in previous studies
from Spain (CSCV-D: 51.11 %; CSCV-F: 51.32 %) [14]
and Chile (CSCV-D: 62.9 %; CSCV-F: 53.5 %) [17].
The psychometric properties of the CSCV in the
studied sample of Mexican outpatients with psychosis
were effective when considering CSCV-D and CSCV-D
scale scoring. Nevertheless, scoring by factors was
somewhat problematic, mainly for the factor “restrained
hostility”, with two (out of three) non-significant cor-
rected item-factor correlations, a moderate corrected
item-scale and a marginal α value. The factor “oddness”
had one item (out of three) with a non-significant cor-
rected item-factor correlation and a moderate corrected
item-scale, but its α value remained strong. In contrast,
the factor “fear of losing control” had moderate correla-
tions with all three of its corresponding items, but a
marginal α value. The number of factors and their item
loading pattern did not correspond to those reported in
the original paper [14], an inconvenience also reported
in a study in Chile [17]. The instability of factor struc-
ture might have been influenced by the relatively small
sample in this study, in comparison to the size of those
from Spain (n = 236) [14], and Chile (n = 183) [17]. Al-
though Chilean and Mexican samples yielded equal
number of factors for both scales, further analysis
Table 2 Internal consistency of scales and factors
Number
of items
α Confidence interval Number
of items
α Confidence interval
95 % 95 %
CSCV-D 46 .962 .95–.98 CSCV-F 13 .897 .85–.93
Lack of cognitive apprehension 5 .664 .51–.78 Vital satisfaction 5 .802 .71–.87
Loss of energy 10 .885 .84–.92 Self-esteem 4 .671 .51–.79
Lack of inner control 7 .814 .73–.88 Harmony 4 .753 .63–.84
Difficulty with emotional expression 5 .781 .68–.86
Difficulty with cognitive expression 7 .832 .76–.89
Oddness 3 .710 .56–.82
Fear of losing control 3 .577 .35–.73
Restrained hostility 3 .576 .35–.73
Automatisms 3 .710 .56–.82
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Table 3 Factor loadings for each item onto each factor after rotation
Disfavorable Scale (CSCV-D)
Factor: 1 2 3 4 5 6 7 8 9 10 11
% of variance: 9.758 9.531 8.825 8.271 7.503 6.843 6.491 5.448 5.287 5.215 4.241






















25 .464 .400 .414
29 .483
46 .418 .447
















Gómez-de-Regil BMC Psychiatry  (2016) 16:160 Page 6 of 8
comparing factors’ composition was not possible as the
necessary data from the former was not available. The
CSCV is potentially a very useful QoL assessment tool
in psychotic patients, and produces satisfactory psycho-
metric properties. However, the present results suggest
that scale scoring is more appropriate than factor scor-
ing in this instrument. Further research is needed to
better assess its psychometric properties (particularly
its factor construct validity) and its applicability in
other (non-Spanish-speaking) populations.
Limiting factors in the present study include its small
sample size and use of an exploratory principal component
analysis, both of which restrict the ability to generalize
from its findings. Also, the KMO values for sample ad-
equacy were acceptable, but low. The results from this
sample of Mexican patients with psychosis provide further
evidence in favor of the CSCV as an effective QoL assess-
ment instrument in psychotic patients. As with any other
assessment tool, caution is needed when applying its spe-
cific psychometric features to different populations.
Conclusions
In mental health patients, QoL is now acknowledged as
an important factor. Assessing QoL helps in monitoring
Table 3 Factor loadings for each item onto each factor after rotation (Continued)
19 .726
39 .811































Note: Only loadings ≥ .400 are reported
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overall patient status and promotes better patient-staff
communication. Patient opinion on their QoL also pro-
vides useful information for use in designing and
improving clinical services. The CSCV for psychotic
patients stands out as a useful tool for this purpose,
particularly for mental health professionals in Spanish-
speaking countries. The present results support the
CSCV as a valid and reliable instrument, although in-
terpretation is best done using scale scores rather than
factor scores.
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